Terms: = Lymphoma AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
36 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Selinexor With Anti-pd-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell lymphoma Failing Prior L-Asparaginase and pd-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract] [Full Text] [Related]
3. Follicular lymphoma Microenvironment Traits Associated with Event-Free Survival.
Tumedei MM; Piccinini F; Azzali I; Pirini F; Bravaccini S; De Matteis S; Agostinelli C; Castellani G; Zanoni M; Cortesi M; Vergani B; Leone BE; Righi S; Gazzola A; Casadei B; Gentilini D; Calzari L; Limarzi F; Sabattini E; Pession A; Tazzari M; Bertuzzi C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373066
[TBL] [Abstract] [Full Text] [Related]
4. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
5. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
[TBL] [Abstract] [Full Text] [Related]
6. Case report: Immune modulation after pd-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics.
Wang Y; Zhang M; Xue Q; Zhou H; Chen J; Wang H; Zhang Y; Shi W
Front Immunol; 2023; 14():1172307. PubMed ID: 37138889
[TBL] [Abstract] [Full Text] [Related]
7. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Front Immunol; 2023; 14():878953. PubMed ID: 37033971
[TBL] [Abstract] [Full Text] [Related]
8. Coexpression of PD-L1/pd-1 with CXCR3/CD36 and IL-19 Increase in Extranodal lymphoma.
Saber MM
J Immunol Res; 2023; 2023():4556586. PubMed ID: 36726488
[TBL] [Abstract] [Full Text] [Related]
9. Milestones in Hematology and Oncology: From Fatal to Curable Disease.
Amzai G; Karanfilski O
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2022 Jul; 43(2):145-157. PubMed ID: 35843924
[No Abstract] [Full Text] [Related]
10. [Expression of PD-L1 and pd-1 in Pathological Tissue of Patients Newly Diagnosed with Diffuse Large B-Cell lymphoma].
Bao F; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):778-783. PubMed ID: 35680805
[TBL] [Abstract] [Full Text] [Related]
11. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract] [Full Text] [Related]
12. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
[TBL] [Abstract] [Full Text] [Related]
13. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C; Palazón-Carrión N; Martin Garcia-Sancho A; Nogales-Fernandez E; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Rueda Dominguez A; Casanova-Espinosa M; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Labrador J; Salar-Silvestre A; Rodriguez-Abreu D; Galvez-Carvajal L; Provencio M; Sánchez-Beato M; Guirado-Risueño M; Espejo-García P; Lejeune M; Álvaro T; Sánchez-Margalet V; de la Cruz-Merino L; ; ;
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158317
[TBL] [Abstract] [Full Text] [Related]
14. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract] [Full Text] [Related]
15. Improved clinical outcome in a randomized phase II study of anti-pd-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract] [Full Text] [Related]
16. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract] [Full Text] [Related]
17. Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell lymphoma.
Gao Y; Liu F; Sun J; Wen Y; Tu P; Kadin ME; Wang Y
J Invest Dermatol; 2021 Mar; 141(3):607-618.e6. PubMed ID: 32771472
[TBL] [Abstract] [Full Text] [Related]
18. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts clinical outcome and Anti-pd-1 Response in Follicular lymphoma.
Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
[TBL] [Abstract] [Full Text] [Related]
20. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
[TBL] [Abstract] [Full Text] [Related]
[Next]
